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Activation of PKA by cAMP agonists, such as 8-Cl-cAMP activation, selectively causes rapid apoptosis in v-abl transformed fibroblasts
by inhibiting the Raf-1 kinase. Here we investigated whether 8-Cl-cAMP is useful for the treatment of chronic myelogenous leukaemia
(CML), which is hallmarked by the expression of the p210
bcr/abl oncogene. Autologous bone marrow transplantation is a feasible
alternative for patients with no suitable donor, but hampered by the risk of relapse due to the persistence of leukaemia cells in the
transplant. To study the effects of 8-Cl-cAMP on primary leukaemic cells, bone marrow cells (BMCs) from eight CML patients (one at
diagnosis, three in chronic and four in accelerated phase) were treated. Ex vivo treatment of BMCs obtained in chronic phase of CML
with 100mM 8-Cl-cAMP for 24–48h led to the selective purging of Philadelphia Chromosome (Ph1 chromosome) without toxic side
effects on BMCs from healthy donors as measured by colony-forming unit (CFU) assays. BMCs from patients in accelerated phase
showed selective, but incomplete elimination of Ph1 chromosome positive colony forming cells. The mechanism of 8-Cl-cAMP was
investigated in FDCP-mix cells transformed by p210
bcr/abl, a cell culture model for CML. The results showed that 8-Cl-cAMP reduced
DNA synthesis and viability independent of Raf inhibition as Raf inhibitors had no effect. MEK inhibitors interfered with DNA
synthesis, but not with viability. In summary, our results indicate that 8-Cl-cAMP could be useful to purge malignant cells from the
bone marrow of patients with CML and certain other forms of leukaemias.
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The activation of signalling pathways due to the constitutive
expression of the Bcr-Abl oncogene plays a major role in the
pathogenesis of some leukaemias, in particular chronic myelogen-
ous leukaemia (CML). CML is the major adulthood leukaemia
characterised by the Philadelphia chromosome (Ph1 chromosome,
t:9/22), a chromosomal translocation where bcr sequences from
chromosome 22 are juxtaposed to c-abl on chromosome 9 leading
to the expression of an atypical fusion-protein p210
bcr-abl
(Butturini et al, 1996). In its chronic phase CML is hallmarked
by abnormally sustained cell survival rather than excessive
proliferation and is relatively well controlled by cytoreductive
chemotherapy. However, the chronic phase inevitably turns into
an acute phase of blast crisis where leukaemic blast cells proliferate
rapidly and aggressively with fatal consequences.
p210
bcr-abl is a constitutively activated tyrosine kinase that
activates numerous cellular signalling pathways including the Raf–
MEK–ERK pathway, which is critical for malignant transforma-
tion. A tyrosine kinase inhibitor for p210
bcr-abl, CGP-57148 now
called STI571, has sparked great interest as it dramatically
increased the number of patients achieving complete remission.
However, almost half of the patients treated in the chronic phase
remain Ph1 chromosome positive with the inherent risk of relapse.
Indeed, many patients treated with STI571 in the acute phase
relapse rapidly (La Rosee et al, 2002). This probably relates to the
fact that STI571 is inhibiting proliferation rather than eliminating
the leukaemic cells (Beran et al, 1998; La Rosee et al, 2002). Despite
the addition of STI571 to the clinical arsenal bone marrow and
peripheral blood stem cell transplantation (PBSCT) remains a
mainstay of therapy. For autologous PBSCT stem cells are
harvested from peripheral blood after stimulation with G-CSF at
the time of clinical remission. A proportion of patients responds at
least initially to autologous PBSCT (Reiffers et al, 1994). Regardless
whether PBSCT or autologous bone marrow transplantation is
used, it is crucial to eliminate leukaemic cells from the transplant
in order to avoid the transfer of leukaemic cells back to the patient.
For CML the logical target that distinguishes normal cells from
leukaemic cells is p210
bcr-abl. This fusion protein aberrantly
activates a number of signalling pathways that act in concert to
transform cells. Thus, these pathways emanating from p210
bcr-abl
are all potential targets for therapeutic intervention. Prominent
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stargets are the Raf-1 kinase and the c-Myc transcription factor.
p210
bcr-abl induces c-Myc expression in haematopoietic cells
(Sawyers et al, 1992; Sawyers, 1993; Weissinger et al, 1993). The
deregulation of c-Myc expression has been shown to be required
for transformation by oncogenic abl genes (Sawyers, 1993;
Weissinger et al, 1993). p210
bcr-abl also activates Raf-1 and the
MEK–ERK pathway. The canonical Raf-MEK–ERK pathway is
often perceived as a linear signalling module that mediates cell
proliferation, transformation and survival (Weissinger et al, 1997).
We have shown previously that the activation of the cAMP
dependent protein kinase A (PKA) with synthetic agonist drugs
such as 8-Chloro-cyclic Adenosine Monophosphate (8-Cl-cAMP)
results in the inhibition of Raf-1 kinase activity and rapid
apoptosis induction in v-abl transformed fibroblasts. Apoptosis
occurred despite a high constitutive activity of ERK suggesting that
Raf-1 uses a different pathway to ensure cell viability (Weissinger
et al, 1997).
These observations led us to explore the use of 8-Cl-cAMP for
the treatment of CML bone marrow cells for ex vivo for the purging
of leukaemic bone marrow or for the treatment of leukaemic
patients. 8-Cl-cAMP is one of the most stable compounds that
activate PKA (Schwede et al, 2000) and can be manufactured in
quantities and quality sufficient for clinical use. In fact, the
antitumour activity of 8-Cl-cAMP has been under study for a
number of years, including clinical studies for the treatment of
tumours (Cho-Chung et al, 1995; Tortora et al, 1995; Propper et al,
1999). To date, mainly solid tumours like breast carcinomas were
studied. In this report we present data indicating that treatment
with 8-Cl-cAMP can provide an effective method for purging bone
marrow prior to autologous transplantation, targeting specifically
the p210
bcr/abl transformed cells.
PATIENTS AND METHODS
Patients
The studies were approved by the institutional ethics committees
of Munich and Hannover. Bone marrow from healthy donors, eight
patients with CML (five males and three females age range: 25–49)
in haematological chronic phase or at more advanced stages was
obtained after informed consent.
Synthesis of 8-Cl-cAMP
Preparation of 8-Cl-cAMP was performed as described with minor
modifications (Brentnall and Hutchinson, 1972; Schwede et al,
2000). Briefly, 30g (85.47mmol) cAMP, sodium salt, were
suspended in 2000ml DMF and reacted with 87g (171mmol)
tetrabutylammonium iodotetrachloride for 18h. The reaction
mixture was poured into 3000ml water and extracted with
chloroform (3 250ml) to remove excess of reagent. The resulting
solution was concentrated under reduced pressure. 8-Cl-cAMP was
purified and isolated by means of column liquid chromatography
using silica-base reversed phase material (Merck, Germany,
LiChroprep
s Rp-18) (Cummings et al, 1994). The product
containing fractions were collected and evaporated to produce
13.95g (36.18mmol) 8-Cl-cAMP, sodium salt, with a purity of
499% (yield: 42.3%).
Cell lines
FDCP-mix cells expressing temperature-sensitive p210
bcr/abl
(Pierce et al, 1998) were cultured in Fisher’s medium, 20% vv
 1
horse serum and 5% vv
 1 murine IL-3 conditioned medium (CM)
from the X63Ag8-653 myeloma cell line as a source of murine IL-3
(Karasuyama and Melchers, 1988).
Long-term culture and colony-forming units (CFU)
The cells were resuspended in LTC-medium supplemented with
12.5% horse serum (Hyclone, Munich, Germany) and 10
 5 M
hydrocortisone at a density of 2 10
6 cellsml
 1 and cultured for
4–6 weeks on autologous feeder layers (LTC-medium, Iscoves
Mod. Dulbecco’s medium 340mOsm, Gibco BRL, Bethesda, USA).
Cells were cultured in duplicates and incubated with medium
alone, 50 or 100mM 8-Cl-cAMP for 24h (summarised in Figure 1).
Subsequently, cells were washed and resuspended in LTC medium.
Nonadherent cells (NADC) were harvested in weekly intervals and
resuspended in MethoCult GF H4434 (Stem Cell Technology,
Munich, Germany). Colonies were counted after 7 days and
evaluated according to standard clinical haematological technique.
Nonspecific toxicity testing of 8-Cl-cAMP
The nonspecific toxicity of 8-Cl-cAMP on bone marrow cells was
tested using marrow mononuclear cells (MNC) from healthy
donors as outlined in Figure 1. The MNCs were cultured at a
density of 2 10
6cellsml
 1 in LTC medium as described above in
the presence or absence of 8-Cl-cAMP for 24h. Subsequently, the
cells were washed and grown in long-term culture medium. In
total, 2 10
5cellsml
 1 were used for CFU assays. At the end of the
long-term culture (4–6 weeks), the adherent cells (ADC) as well as
the NADC were harvested and analysed in the same manner.
Cytogenetic analyses
After completion of the CFU assays, colonies were picked and
analysed for Ph1 chromosome positive colonies. Cytogenetic
analyses were essentially performed as described (Dube et al,
1981). Briefly, cell division was arrested in metaphase by the
addition of 100ml of a colchicine solution (1mgml
 1 in a-minimal
essential medium) to 1ml of cell suspension for 12h. The cells
were subsequently transferred to poly-L-lysine-coated slides and
incubated in 0.2ml of 0.075moll
 1 KCl at room temperature for
10min. Cells were fixed by gently dropping 100ml cold methanol
on the slide. The excess of the fixative was removed with absorbent
paper and slides were dried on a hot plate at 551C. After repeated
cold fixation for 15min, the cells were used for banding and
cytogenetic analyses.
Growth curves
8-Cl-cAMP was added to the cultures as indicated on day 0 and
was not replenished during the culture. FDCP-mix cells were
plated in 24-well plates at a density of 2 10
5cellsml
 1. The MEK
inhibitors (U0126, PD98059) and raf kinase inhibitors, raf kinase
inhibitor 1 (Raf KI) and ZM 336372, were purchased from
Calbiochem, UK. Survival and proliferation assays were performed
as previously described (Pierce et al, 1998).
Viability assay
FDCP-mix cells were washed and resuspended (4 10
5cellsml
 1)
in Fisher’s medium supplemented with 20% (vv
 1) HS. The cells
were treated with 8-Cl-cAMP (100mM) in the absence of murine IL-
3 (0.5ngml
 1). Samples were taken after 24, 48 and 72h in culture.
Cell viability was analysed by flow cytometry using the annexin V-
FITC, propidium iodide (PI) based assay (R&D Systems, Oxford,
UK) as previously described (Francis et al, 2000). Samples were
analysed using a FacsVantage flow cytometer (Becton Dickinson
Co., Mountain View, CA, USA). Viable cells (unstained), early
apoptotic cells (Annexin V positive) and late apoptotic and/or
necrotic cells were analysed. Results are shown7s.e.m. (n¼3).
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sRESULTS
PKA-activation resulted in a transient growth inhibition of
human bone marrow cells
The nonspecific toxicity of 8-Cl-cAMP was tested on human bone
marrow cells (BMC) of healthy donors (Table 1). In total, 15 flasks
of cells per donor were set up for long-term cultures after
treatment with 8-Cl-cAMP, five for each condition (control, 50mM
and 100mM 8-Cl-cAMP; Figure 1). BMCs taken at week 0
immediately after treatment with 8-Cl-cAMP showed a reduction
of cell numbers and a concomitant reduction of colonies arising in
the CFU assays. However, at all subsequent timepoints, ranging
from 1 to 5 weeks, comparable numbers of CFU-initiating cells
were obtained from treated and untreated BMC cultures. This is
summarised in Table 1 showing CFUs obtained from week 5
cultures as example. Thus, 8-Cl-cAMP only caused a transient
impairment of CFU capacity in BMCs from healthy donors that
was readily reversed at longer time points. This is consistent with
our earlier observations (Weissinger et al, 1997) that untrans-
formed cells only respond to PKA activation with an initial,
transient inhibition of proliferation.
Ph1 chromosome positive colony forming cells are
selectively eliminated by 8-Cl-cAMP
Since no severe nonspecific toxicity was observed that would
prohibit treatment with 8-Cl-cAMP, bone marrow MNCs of eight
patients with CML were treated in the same manner (Table 2).
Three patients were in the chronic phase of CML undergoing
cytoreductive treatment, one patient was at diagnosis and
four were in the accelerated phase or blast crisis. In all cases,
treatment with 8-Cl-cAMP substantially reduced the number of
Ph1 chromosome positive colonies. The incubation with 50mM
Table 1 Colony formation assays and cytogenetic analyses on normal volunteer marrow MNC
Cultures Granulocytes (G) Eosinophiles (Eo) Macrophages (M) Erythrocytes (E) Mixed colonies (GM) Blasts Total no.
Week 0 control 49 2 61 128 12 7 259
8-Cl-cAMP (100mm) 27 4 18 100 7 9 145
Week 5 control ADC 57 2 16 6 2 5 88
8-Cl-cAMP(100mm) ADC 70 2 10 30 14 22 148
Data obtained after treatment of normal marrow MNC with 8-Cl-cAMP are summarised. The cells were resuspended at 2.5 10
5cellsml
 1 as described in Figure 1. The effects
of treatment with 8-Cl-cAMP (one single exposure of the cells for 24h) on colony formation was observed at week 0 and after week 5.2 10
5cellsml
 1 were plated in soft agar
for colony formation in week 1 or after long-term culture. The nonadherent cell fraction did not yield significant amounts of colonies with or without 8-Cl-cAMP treatment after
5 weeks, thus only the adherent cells (ADC) are shown. Colonies were judged by their typical histological appearance according to haematological criteria: G¼granulocyte;
Eo¼eosinophiles; M¼macrophages; E¼erythrocytes; GM¼mixed colonies, Granulocytes and macrophages.
Table 2 Percentage Philadelphia chromosome positive colonies (CFU-GM) in patients with CML in the presence or absence of 8Cl-cAMP
Week 0 Week 5
Patient ID Control 8Cl-cAMP 50lm 8Cl-cAMP 100lm Control 8Cl-cAMP 50lm 8Cl-cAMP 100lm
1216 (cp) 100 (2/2) 100 (20/20) 100 (28/28) ND 14 (3/21) 0 (0/15)
1206 (cp) 100 (12/12) ND 70 (12/17) 83 (30/36) ND 0 (0/15)
1726 (cp) 100 (62/62) ND 100 (25/25) 83 (26/29) ND 0 (0/37)
166 (D) 100 (6/6) 100 (15/15) ND 100 (20/20) 46 (7/15) ND
A97/3 (ap) 100 (21/21) ND 100 (30/30) 100 (5/5) ND 83 (5/6)
371 (ap) 81 (27/33) ND 92 (24/26) 81 (27/33) ND 33 (1/3)
361 (ap) 100 (30/30) ND 100 (19/19) 100 (30/30) ND 50 (2/4)
341 (ap) 100 (40/40) ND 96 (26/27) 100 (34/34) ND 62 (5/8)
The Ph1 chromosome positive colonies (in %) arising from patient bone marrow cells in percent are summarised, the actual number of colonies is given in parenthesis (Ph1
chromosome+/total number). MNC were incubated for 24h without or with 50 or 100mm of 8-Cl-cAMP as indicated, washed and resuspended in long-term culture medium
(Dexter). CFU-assays were setup in week 0 and weekly thereafter. CFU-GM of the adherent fraction of the cells (ADC) is shown, since there were only few colonies in the non-
adherent fraction at this time. Ph1 chromosome status was determined by cytogenetic analysis. cp¼chronic phase; D¼diagnosis; ap¼accelerated phase; ND¼not determined.
Procedure for PKA activation in marrow MNC
1x 10
7 MNC + 
100 µM 8-Cl-cAMP, 
24 h
1x 10
7 MNC + 
PBS, 24 h
1x 10
7 MNC + 
50 µM 8-Cl-cAMP, 
24 h
5 flasks ( 2 x 106 cells ml-1) for each group
CFU assays (2x10
5/ml) week 0 and weekly afterwards 
Figure 1 Procedure for PKA activation in bone marrow mononuclear
cells (MNC). Marrow MNC were harvested, washed and resuspended in
LTC medium. Separate flasks were generated for long-term culture and 8-
Cl-cAMP was added as indicated. After 24h cells were washed, and
expanded in long-term cultures as described. CFU assays were setup
weekly with the nonadherent cells (NADC). At the end of the long-term
culture, adherent cells (ADC) and nonadherent cells (NADC) were
harvested and analysed in separate CFU-assays.
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positive colonies to 14 and 46%, respectively, but never led to
a complete elimination of the Ph1 chromosome positive
progenitor cells. Therefore, 100mM 8-Cl-cAMP was used in further
experiments.
In CFU assays prepared from cultures at week 0 all colonies were
Ph1 chromosome positive, and no difference was observed
between the treated and the untreated cells. However, treatment
with 8-Cl-cAMP resulted in a significant reduction of Ph1
chromosome positive CFUs prepared after 5 weeks of culture
depending on the stage of disease. In three patients undergoing
cytoreductive therapy, the treatment with 100mM 8-Cl-cAMP led to
a complete loss of Ph1 chromosome positive colonies after 5 weeks
of culture. In the absence of 8-Cl-cAMP only a small reduction of
Ph1 chromosome positive colonies was observed after 5 weeks of
culture, with more than 80% of the colonies remaining Ph1
chromosome positive. Cells from one untreated patient and four
patients in advanced stages of CML exhibited a reduction of cells
with a significant loss of Ph1 chromosome positive colonies
ranging from 83 to 33%. Interestingly, after treatment with 8-Cl-
cAMP Ph1 chromosome negative colonies appeared in CFU assays
prepared from patients in the accelerated phase of CML, whereas
in the untreated controls 100% of the colonies were Ph1
chromosome positive.
Studies to investigate the molecular mechanism of 8-Cl-
cAMP
Given the encouraging results obtained with 8-Cl-cAMP in clinical
samples and patients we investigated the molecular basis of the
activity of 8-Cl-cAMP in particular with regard to its effects on cell
proliferation and survival. Due to technical reasons such as
freshness and instability of the material, these studies are
extremely difficult in primary clinical samples. Therefore, we used
bcr-abl transformed FDCP-mix p210
bcr/abl cells, a well charac-
terised cell culture model system for CML (Pierce et al, 1998).
These cells are conditionally transformed by expression of a
temperature-sensitive p210
bcr/abl protein. They still remain IL-3
dependent although p210
bcr/abl sensitises them to the effects of
IL-3, when cultured at the permissive temperature of 321C. The
main effect of p210
bcr/abl is to enhance viability under conditions of
low IL-3 levels (0.01–0.1ngml
 1) (Pierce et al, 1998).
Our previous studies with v-abl transformed fibroblasts
(Weissinger et al, 1997) had indicated that PKA activation could
downregulate the activity of Raf-1 and thereby cause apoptosis in
these cells. This would provide a plausible explanation for the
effects of 8-Cl-cAMP on CML cells. To test whether this hypothesis
was also applicable to haematopoietic cells we compared 8-Cl-
cAMP to selective pharmacological inhibitors of Raf-1 and MEK.
As observed previously (Pierce et al, 1998) p210
bcr/abl did not
significantly affect DNA synthesis when cells were compared to
parental controls within 24h after shifting them to the permissive
temperature 321C (Figure 2). The two Raf kinase inhibitors (Raf KI
and ZM336372) failed to interfere with IL-3 driven proliferation.
Raf KI even accelerated proliferation in both the control cells and
p210
bcr/abl cells exposed to 10ngml
 1 IL-3. In contrast, both MEK
inhibitors (U0126 and PD98059) interfered with DNA synthesis
and this effect was slightly more pronounced in the p210
bcr/abl cells.
In control cells 8-Cl-cAMP interfered with DNA synthesis only at
high (10ngml
 1) concentrations of IL-3, whereas it blocked
proliferation in p210
bcr/abl cells at all concentrations.
A clear difference emerged when the effects on viability were
assayed using trypan blue exclusion (Figure 3). FDCP-mix cells
have been reported to die by apoptosis following cytokine removal
(Williams et al, 1990). p210
bcr/abl protected cells from the cytotoxic
effects of IL-3 withdrawal, maintaining the viability of almost 40%
of cells 3 days after IL-3 withdrawal. Under these conditions the
viability of the control cells was severely compromised. IL-3 was a
very potent survival factor even at 0.1ngml
 1. Higher concentra-
tions of IL-3 did not improve survival further. Interestingly,
neither MEK inhibitors (Figure 3A) nor Raf inhibitors (Figure 3B)
counteracted effects of p210
bcr/abl or IL-3 on cell viability.
In contrast, 8-Cl-cAMP significantly inhibited the cytoprotective
effect of p210
bcr/abl, but not of IL-3 (Figure 4A). Moreover, 8-Cl-
cAMP preferentially induced cell death in p210
bcr/abl as compared
to control cells. This effect was most pronounced 48 and 72h after
IL-3 withdrawal, suggesting that p210
bcr/abl sensitises cells to killing
by 8-Cl-cAMP. IL-3 protected against 8-Cl-cAMP induced
cytotoxicity suggesting that IL-3 can activate p210
bcr/abl indepen-
dent survival pathways. As trypan blue exclusion (Figure 4A) does
not distinguish between necrotic and apoptotic cell death, we
further tried to dissect the mode of 8-Cl-cAMP induced cell death.
Apoptosis leads to cell surface phospholipid asymmetry resulting
in the exposure of phosphatidylserine (PS) on the outer leaflet of
the cytoplasmic membrane. Annexin V preferentially binds PS and
has been used to detect apoptosis in the FDCP-mix cells (Francis
et al, 2000). In contrast to necrosis, membrane integrity is
maintained during apoptosis precluding staining of DNA by the
membrane impermeable dye propidium iodide (PI). Thus,
apoptosis is indicated by positive staining for annexin V and
negative staining for PI. As shown in Figure 4B measuring viability
as cells that escape apoptosis, that is, stain negative for annexin,
largely parallels the data obtained with the trypan blue exclusion
assay, exception that in this assay the parental FDCP-mix cells also
show a significant decrease in viability in response to 8-Cl-cAMP
48 and 72h after IL-3 removal. Measuring annexin positive and PI
negative, that is, apoptotic cells (Figure 4C) showed a higher rate of
Figure 2 Effect of 8-Cl-cAMP, Raf kinase inhibitors and MEK inhibitors on
the proliferation of FDCP-mix (A) and p210
bcr-abl transformed FDCP-mix
cells (B). Cells were cultured at the permissive temperature in Fisher’s
medium with 20% horse serum and increasing concentrations of IL-3 (0,
0.01, 0.1, 1, 10ngml
 1) as shown on the X-axis. 8-Cl-cAMP (100mM), MEK
inhibitors U0126 (10mM) or PD98059 (50mM), and Raf kinase inhibitors, Raf
kinase inhibitor I (Raf KI, 10mM) and ZM336372 (100mM) were added and
DNA synthesis was assessed by measuring [3H] thymidine incorporation
after 16h. Experiments were carried out in triplicates.
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cAMP did not significantly affect this rate. However, a significant
increase in apoptosis was observed in 8-Cl-cAMP treated p210
bcr/
abl cells 48h after IL-3 withdrawal. Necrotic cell death as measured
by cells staining positive for annexin and PI (Figure 4D) was
enhanced by 8-Cl-cAMP under conditions of IL-3 withdrawal.
Significant increases were observed in control cell 24h, and in the
p210
bcr/abl cells 48 and 72h after IL-3 removal. These results
confirm the data obtained by the trypan blue exclusion assay, and
suggest that 8-Cl-cAMP mediated cytotoxicity includes both
apoptosis and necrotic cell death.
In summary, the inhibitor experiments demonstrated that the
pathways mediating proliferation can be dissociated from path-
ways required for p210
bcr/abl driven cell survival. MEK–ERK
signalling is required for DNA synthesis, but not for viability,
whereas 8-Cl-cAMP can interfere with cell proliferation as well as
survival. More importantly they show that 8-Cl-cAMP preferen-
tially kills p210
bcr/abl cells.
DISCUSSION
In this report we have analysed the influence of PKA-activation on
transformed cells from eight patients with CML. The expression of
p210
bcr/abl is a hallmark of CML. Among other signalling pathways
p210
bcr/abl also activates the Raf–MEK–ERK pathway. We have
previously shown that the inhibition of Raf-1 by 8-Cl-cAMP led to
apoptosis in v-abl transformed fibroblasts, while control cells or
cells expressing the v-raf oncogene showed only a reversible
growth inhibition (Weissinger et al, 1997). Here we demonstrate
that the activation of PKA is a promising approach to selectively
eliminate the Ph1 chromosome positive progenitor cells from
marrow obtained from CML-patients. Despite an initial reduction
of total cell numbers no long-term cytotoxicity was observed when
marrow cells from normal donors were treated with 50 or 100mM
8-CL-cAMP (Table 1). The initial decline in cell numbers is
probably due to the inhibition of proliferation also observed in
untransformed NIH3T3 fibroblasts or even in v-raf transformed
fibroblasts (Weissinger et al, 1997). The reversible inhibition of
normal cell proliferation could potentially be exploited to protect
stem cells during chemotherapy. Thus, combining 8-Cl-cAMP with
classical DNA damaging chemotherapeutic drugs may have the
added benefits of assaulting the leukaemic cells by two routes while
protecting the stem cells at the same time.
Seeking to understand the mechanism of growth inhibition and
apoptosis induced in patient cells, we employed a well-charac-
terised cell culture model of CML, that is, FDCP-mix cells
expressing a temperature-sensitive p210
bcr/abl (Pierce et al, 1998).
An obvious hypothesis emerging from our previous work with v-
abl transformed fibroblasts (Weissinger et al, 1997) was that the
inhibition of Raf-1, but not MEK, would be crucial for the
cytotoxic effects of 8-Cl-cAMP. Therefore, we compared the effects
of 8-Cl-cAMP to Raf-1 and MEK inhibitors. The results clearly
show that MEK activity is required for the proliferation of both
normal and p210
bcr/abl cells. In contrast, MEK activity was not
required for p210
bcr/abl or IL-3 mediated viability. Curiously, Raf-1
inhibitors did not inhibit proliferation or survival, and Raf KI even
enhanced these parameters. These results suggest that Raf-1 does
not play a significant role in mediating proliferation or survival in
these cells. However, the unexpected effects of Raf kinase
inhibitors may be explained by a paradoxical activation of Raf
previously observed with ZM 336372 (Hall-Jackson et al, 1999).
Alternatively, Raf kinase activity may be dispensable for main-
tenance of cell viability, as Raf-1 has been shown to prevent
apoptosis independent of its kinase activity by binding to and
inhibiting the activity of the proapoptotic kinase ASK-1 (Chen et al,
2001). In this scenario, the Raf inhibitors would not be expected to
show any effects, since they are ATP analogues that block kinase
activity but not binding to other proteins. Furthermore, myeloid
cells can activate the ERK pathway independent of Raf (Buscher
et al, 1995), which could explain why the Raf and MEK inhibitors
have different effects. Thus, the inhibitory effects of 8-Cl-cAMP on
the proliferation and viability of p210
bcr/abl cells cannot be
explained by the inhibition of the catalytic activities of Raf-1 and
MEK.
Importantly, 8-Cl-cAMP exhibited significant selective cytotoxi-
city for cells that express p210
bcr/abl. This was shown with the
p210
bcr/abl transformed FDCP-mix cells as well as with primary
bone marrow cells from leukaemic and normal donors. When
marrow was obtained from patients in chronic phase of CML, a
single incubation with 100mM 8-Cl-cAMP for 24h was sufficient to
Figure 3 Effect of MEK inhibitors (A) and Raf kinase inhibitors (B)o n
the viability of FDCP-mix and p210
bcr-abl transformed FDCP-mix cells. Cells
were cultured as in Figure 2. IL-3 was removed and inhibitors were added
at the concentrations described in Figure 2. Cell viability was assessed by
trypan blue exclusion 72h after IL-3 removal. Experiments were carried out
in triplicates.
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cells in vitro. In analogy to our previously published experiments
(Weissinger et al, 1997), the effects of 8-Cl-cAMP treatment and
PKA activation were irreversible in p210
bcr/abl transformed
progenitor cells of CML. Interestingly, in week 0 no elimination
of the Ph1 chromosome positive progenitor cells had occurred.
One explanation is that the induction of cell death requires
proliferating cells. We reason that dividing cells are eliminated,
whereas differentiating progenitors may not be affected by the
activation of PKA. The induction of cell death in the susceptible
progenitor population is reflected by the loss of Ph1 chromosome
positive colonies after treatment as summarised in Table 2.
In conclusion, our results demonstrate that 8-Cl-cAMP can be
useful for the efficient elimination of Ph1 chromosome positive
progenitor cells from bone marrow ex vivo without severe toxic
effects on normal cells. This offers a new method to purge marrow/
stem cell populations from patients with Ph1 chromosome-positive
leukaemias prior to autologous transplantation.
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